期刊文献+

蛋白激酶B siRNA转染胃癌SGC-7901细胞对其侵袭能力的影响 被引量:1

Effect of siRNA Targeting PKB on the Ability of Invasion of Gastric Cancer Cells (SGC-7901)
下载PDF
导出
摘要 目的研究蛋白激酶B(protein kinase B,PKB)小干扰RNA(siRNA)转染人胃癌SGC-7901细胞,探讨转染后抑制癌细胞转移侵袭的可行性.方法应用基因转染技术将蛋白激酶基因片段转染至胃癌SGC-7901细胞中,采用Millicell小室、集落形成实验、流式细胞术等方法观察蛋白激酶BsiRNA转染后对转染组细胞侵袭力的影响.结果与对照组比较转染组的胃癌SGC-7901细胞克隆增殖速度和侵袭能力明显减弱(P<0.01),提示转染组siRNA能特异性抑制蛋白激酶B基因的活化,即蛋白激酶B基因的siRNA片断可抑制胃癌SGC-7901细胞的克隆增殖和癌细胞转移侵袭.结论应用RNAi使蛋白激酶B基因沉默能有效抑制人胃癌SGC-7901细胞的克隆生长,并在一定程度上阻止了癌细胞的侵袭和转移,其作用机理值得进一步的深入研究. Objective To study the effect of PKB gene (Akt2) silencing on the invasion of gastric cancer cell line SGC-7901 in vitro, and to investigate feasibility of small interfering RNA targeting PKB gene in inhibiting invasion of gastric cancer. Methods The siRNA of PKB gene was transfected into SGC-7901 cell, the ability of SGC - 7901 invasion in vitro was assessed by cell migration and invasion assay in Boyden chamber, clone form rate was observed by clone form assay and the change of cell cycle distribution and apoptosis of SGC-7901 ceils was detected by flow-cytometry. Results After treatment with PKB siRNA, compared with control group, Akt2 siRNA group showed lower invasion ability ( P 〈 0.01) and decreased clone form rate in vitro ( P 〈 0.01) with PKB gene silencing. Conclusions Small interfering RNA targeting PKB gene may become one of effective methods in inhibiting clone form, migration and invasion of gastric cancer. It appears that PKB can be a novel target for the treatment of gastric cancer. It' s mechanism of inhibiting invasion ability deserves further study.
出处 《昆明医学院学报》 2009年第5期43-46,共4页 Journal of Kunming Medical College
关键词 胃癌 小干扰RNA 蛋白激酶B 侵袭力 Stomach neoplasm siRNA PKB Invasion
  • 相关文献

参考文献16

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 2OENSUU H,FLETCHER.Management of malignant gastrointestinal stromal tumor[J].Lancet Oncol,2002,3:655-664. 被引量:1
  • 3TERRANOVA V P.Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells[M].Proc Nat Acad Sci USA,1986,83:465. 被引量:1
  • 4ALBINI A.A rapid in vitro assay for quantitating the invasive potential of tumor cells[J].Cancer Research,1987,47:3239. 被引量:1
  • 5JIANG T L,LIU R H,SALMON S E.Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells[J].Investigational New Drugs,1983,1 (1):21-25. 被引量:1
  • 6SOURBIER C,LINDNER V,LANG H.Akt siRNA,The phosphoinositide 3-Kinase/Akt pathway:A new target in human renal cell carcinoma therapy[J].Cancer Research,2006,66(10):5130-5142. 被引量:1
  • 7ZHANG Y A,NEMUNAITIS J,SAMUEL S K.Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA[J].Cancer Research,2006,66(19):9736-9743. 被引量:1
  • 8SITHANANDAMG,FORNWALDLW,FIELDS J.Inac tivation of ErhB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma[J].Oncogene,2005,24 (11):1847 -1859. 被引量:1
  • 9OGAWA E,OKUYAMA R,IKAWA S,et al.P51/p63 inhibits ultraroolet B-induced apoptosis via Akt actiration[J].Oncogene,2008,27:848-856. 被引量:1
  • 10KANG C S.Study on AKT2 expression in gliomasand correlative analysis with tumor cell p roliferation and invasion[J].Chin J Path,2004,33:4642-4645. 被引量:1

二级参考文献17

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002. 被引量:1
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016. 被引量:1
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40. 被引量:1
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328. 被引量:1
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a. 被引量:1
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a. 被引量:1
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281. 被引量:1
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235. 被引量:1
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020. 被引量:1

共引文献267

同被引文献16

  • 1Lcee SH,Kim HS,Park WS. Non-small cell lung cancers frequently express phosphorylated Akt,an immunohistochemical study[J].Acta Pathologica,Microbiologica Et Immunologica Scandinavica,2002,(7-8):587-592. 被引量:1
  • 2Mitsudomi T,Yatabe Y. Epidermal growth factor receptor in relation to tumor development:EGFR gene and cancer[J].FEBS Journal,2010,(02):301-308.doi:10.1111/j.1742-4658.2009.07448.x. 被引量:1
  • 3Itoh N,Semba S,Ito M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma[J].Cancer,2002,(12):3127-3134. 被引量:1
  • 4Schlieman MG,Fahy BN,Ramsamooj R. Incidence,mechanism and prognostic value of activated AKT in pancreas cancer[J].British Journal of Cancer,2003,(11):2110-2115.doi:10.1038/sj.bjc.6601396. 被引量:1
  • 5Sebastian S,Settleman J,Reshkin SJ. The complexity of targeting EGFR signalling in cancer:from expression to tunover[J].Biochim Biophys Acta(BBA)-Reviews on Cancer,2006,(01):120-139. 被引量:1
  • 6Nautiyal J,Yu YJ,Aboukameel A. ErbB-inhibitory protein:a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells[J].Molecular Cancer Therapeutics,2010,(06):1503-1514. 被引量:1
  • 7Coticchia CM,Revankar CM,Deb TB. Calmodulin modulates Akt activity in human breast cancer lines[J].Breast Cancer Research and Treatment,2009,(03):545-560.doi:10.1007/s10549-008-0097-z. 被引量:1
  • 8Lang SA,Klein D,Moser C. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo[J].Molecular Cancer Therapeutics,2007,(03):1123-1132. 被引量:1
  • 9Lieto E,Ferrarccio F,Orditura M. Expression of vascular endothelial growth factor (vegf) and epidermal growth factor receptor(EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients[J].Annals of Surgical Oncology,2008,(01):69-79. 被引量:1
  • 10李勇,李建英,陈丰霖,陈治新.蛋白激酶B和15-脂氧合酶-1在胃癌中的表达及其临床意义[J].胃肠病学和肝病学杂志,2009,18(10):938-941. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部